Targeting hepatic glucose metabolism in the treatment of type 2 diabetes

Amy K. Rines, Kfir Sharabi, Clint D.J. Tavares, Pere Puigserver*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

258 Scopus citations


Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia. Although current diabetes treatments have exhibited some success in lowering blood glucose levels, their effect is not always sustained and their use may be associated with undesirable side effects, such as hypoglycaemia. Novel antidiabetic drugs, which may be used in combination with existing therapies, are therefore needed. The potential of specifically targeting the liver to normalize blood glucose levels has not been fully exploited. Here, we review the molecular mechanisms controlling hepatic gluconeogenesis and glycogen storage, and assess the prospect of therapeutically targeting associated pathways to treat type 2 diabetes.

Original languageAmerican English
Pages (from-to)786-804
Number of pages19
JournalNature Reviews Drug Discovery
Issue number11
StatePublished - 1 Nov 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.


Dive into the research topics of 'Targeting hepatic glucose metabolism in the treatment of type 2 diabetes'. Together they form a unique fingerprint.

Cite this